{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:58:34Z","timestamp":1792792714706,"version":"4.5.0"},"reference-count":134,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaacap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jaac.2022.05.012","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T21:43:43Z","timestamp":1655156623000},"page":"318-334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Systematic Review and Meta-analysis: Pharmacological and Nonpharmacological Interventions for Persistent Nonepisodic Irritability"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5500-6950","authenticated-orcid":false,"given":"Rosanna","family":"Breaux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0492-0643","authenticated-orcid":false,"given":"Raman","family":"Baweja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4916-0828","authenticated-orcid":false,"given":"Hana-May","family":"Eadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6702-2333","authenticated-orcid":false,"given":"Delshad M.","family":"Shroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4558-8883","authenticated-orcid":false,"given":"Annah R.","family":"Cash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9455-8974","authenticated-orcid":false,"given":"Courtney S.","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3845-4844","authenticated-orcid":false,"given":"Amy","family":"Knehans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5563-3417","authenticated-orcid":false,"given":"James G.","family":"Waxmonsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"S1","key":"10.1016\/j.jaac.2022.05.012_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00787-012-0355-9","article-title":"Mood dysregulation","volume":"22","author":"Mikita","year":"2012","journal-title":"Eur Child Adoles Psychiatry"},{"issue":"4","key":"10.1016\/j.jaac.2022.05.012_bib2","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/CHI.0b013e3181984f30","article-title":"Longitudinal outcome of youth oppositionality: irritable, headstrong, and hurtful behaviors have distinctive predictions","volume":"48","author":"Stringaris","year":"2009","journal-title":"J\u00a0Am Acad Child Psychiatry"},{"key":"10.1016\/j.jaac.2022.05.012_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/med\/9780199674541.003.0008","article-title":"Irritability in autism spectrum disorders","author":"Stringaris","year":"2015","journal-title":"Disruptive Mood"},{"issue":"7","key":"10.1016\/j.jaac.2022.05.012_bib4","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jaac.2016.04.014","article-title":"The status of irritability in psychiatry: a conceptual and quantitative review","volume":"55","author":"Vidal-Ribas","year":"2016","journal-title":"J\u00a0Am Acad Child Psychiatry"},{"issue":"3","key":"10.1016\/j.jaac.2022.05.012_bib5","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.chc.2021.04.014","article-title":"Chronic irritability in youth","volume":"30","author":"Leibenluft","year":"2021","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"issue":"1","key":"10.1016\/j.jaac.2022.05.012_bib6","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1037\/0022-3514.78.1.122","article-title":"Temperament and personality: origins and outcomes","volume":"78","author":"Rothbart","year":"2000","journal-title":"J\u00a0Pers Soc Psychol"},{"issue":"1","key":"10.1016\/j.jaac.2022.05.012_bib7","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1196\/annals.1301.022","article-title":"Irritability in pediatric mania and other childhood psychopathology","volume":"1008","author":"Leibenluft","year":"2003","journal-title":"Ann NY Acad Sci"},{"issue":"2","key":"10.1016\/j.jaac.2022.05.012_bib8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00787-010-0150-4","article-title":"Irritability in children and adolescents: a challenge for DSM-5","volume":"20","author":"Stringaris","year":"2011","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"2","key":"10.1016\/j.jaac.2022.05.012_bib9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cpr.2009.11.004","article-title":"Emotion-regulation strategies across psychopathology: a meta-analytic review","volume":"30","author":"Aldao","year":"2010","journal-title":"Clin Psychol Rev"},{"key":"10.1016\/j.jaac.2022.05.012_bib10","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/med\/9780199798261.003.0072","article-title":"Pediatric bipolar disorder","author":"Leibenluft","year":"2011","journal-title":"Neurobiol Ment Illness"},{"key":"10.1016\/j.jaac.2022.05.012_bib11","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"issue":"2","key":"10.1016\/j.jaac.2022.05.012_bib12","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.beth.2019.10.009","article-title":"Irritability as a transdiagnostic vulnerability trait: current issues and future directions","volume":"51","author":"Beauchaine","year":"2020","journal-title":"Behav Ther"},{"issue":"7","key":"10.1016\/j.jaac.2022.05.012_bib13","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/jcpp.12823","article-title":"Practitioner review: definition, recognition, and treatment challenges of irritability in young people","volume":"59","author":"Stringaris","year":"2017","journal-title":"J\u00a0Child Psychol Psychiatry"},{"issue":"6","key":"10.1016\/j.jaac.2022.05.012_bib14","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1089\/cap.2015.0005","article-title":"Tolerability, safety, and benefits of risperidone in children and adolescents with autism: 21-month follow-up after 8-week placebo-controlled trial","volume":"25","author":"Aman","year":"2015","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"12","key":"10.1016\/j.jaac.2022.05.012_bib15","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/00004583-200312000-00011","article-title":"Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials","volume":"42","author":"Arnold","year":"2003","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"10.1016\/j.jaac.2022.05.012_bib16","volume":"2","author":"Wehmeier","year":"2008","journal-title":"Child Adolesc Psychiat Mental Health"},{"issue":"10","key":"10.1016\/j.jaac.2022.05.012_bib17","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jaac.2010.07.007","article-title":"National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007","volume":"49","author":"Comer","year":"2010","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"9","key":"10.1016\/j.jaac.2022.05.012_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaac.2014.05.010","article-title":"Growth in the concurrent use of antipsychotics with other psychotropic medications in Medicaid-enrolled children","volume":"53","author":"Kreider","year":"2014","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"8","key":"10.1016\/j.jaac.2022.05.012_bib19","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1517\/14740338.2015.1053457","article-title":"Safety and tolerability of antipsychotic-mood stabilizer co-treatment in the management of acute bipolar disorder: results from a systematic review and exploratory meta-analysis","volume":"14","author":"Galling","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"9","key":"10.1016\/j.jaac.2022.05.012_bib20","first-page":"S436","article-title":"Irritability and mood dysregulation in children\u2500a dynamic construct changing concepts","volume":"16","author":"Ray","year":"2019","journal-title":"Indian J Psychiatry"},{"issue":"7","key":"10.1016\/j.jaac.2022.05.012_bib21","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.16m10884","article-title":"Differential risk of increasing psychotropic polypharmacy use in children diagnosed with ADHD as preschoolers","volume":"78","author":"Winterstein","year":"2017","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"7","key":"10.1016\/j.jaac.2022.05.012_bib22","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaac.2020.09.023","article-title":"Trends in antipsychotic medication use in young privately insured children","volume":"60","author":"Bushnell","year":"2021","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"7","key":"10.1016\/j.jaac.2022.05.012_bib23","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.7850","article-title":"Antipsychotic treatment among youths with attention-deficit\/hyperactivity disorder","volume":"2","author":"Sultan","year":"2019","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.jaac.2022.05.012_bib24","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1177\/1094428106291059","article-title":"(2008). Estimating effect sizes from pretest-posttest-control group designs","volume":"11","author":"Morris","year":"2008","journal-title":"Organization Res Methods"},{"issue":"9","key":"10.1016\/j.jaac.2022.05.012_bib25","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/jpepsy\/jsp004","article-title":"How to select, calculate, and interpret effect sizes","volume":"34","author":"Durlak","year":"2009","journal-title":"J\u00a0Pediatr Psychol"},{"key":"10.1016\/j.jaac.2022.05.012_bib26","series-title":"Introduction to Meta-analysis","author":"Borenstein","year":"2011"},{"issue":"5","key":"10.1016\/j.jaac.2022.05.012_bib27","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/da.22461","article-title":"Psychological treatment of depression in college students: a metaanalysis","volume":"33","author":"Cuijpers","year":"2016","journal-title":"Depress Anxiety"},{"issue":"1","key":"10.1016\/j.jaac.2022.05.012_bib28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pnpbp.2009.09.012","article-title":"Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism","volume":"34","author":"Akhondzadeh","year":"2010","journal-title":"Prog Neuro-Psychopharmacol Biolog Psychiatry"},{"issue":"8","key":"10.1016\/j.jaac.2022.05.012_bib29","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1176\/appi.ajp.159.8.1337","article-title":"Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence","volume":"159","author":"Aman","year":"2002","journal-title":"Am J Psychiatry"},{"issue":"5","key":"10.1016\/j.jaac.2022.05.012_bib30","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/cap.2009.0120","article-title":"Line-item analysis of the aberrant behavior checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder","volume":"20","author":"Aman","year":"2010","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"10","key":"10.1016\/j.jaac.2022.05.012_bib31","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1097\/01.chi.0000231976.28719.2a","article-title":"Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial","volume":"45","author":"Arnold","year":"2006","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"11","key":"10.1016\/j.jaac.2022.05.012_bib32","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.jaac.2012.08.028","article-title":"Research Units of Pediatric Psychopharmacology (RUPP) Autism Network randomized clinical trial of parent training and medication: one-year follow-up","volume":"51","author":"Arnold","year":"2012","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"10.1016\/j.jaac.2022.05.012_bib33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00213-012-2796-8","article-title":"Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial","volume":"225","author":"Asadabadi","year":"2013","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1016\/j.jaac.2022.05.012_bib34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/WNF.0000000000000405","article-title":"Does pregnenolone adjunct to risperidone ameliorate irritable behavior in adolescents with autism spectrum disorder? A randomized, double-blind, placebo-controlled clinical trial","volume":"43","author":"Ayatollahi","year":"2020","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"10.1016\/j.jaac.2022.05.012_bib35","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2478\/v10134-010-0024-9","article-title":"Early-stage visual processing abnormalities in high-functioning autism spectrum disorder (ASD)","volume":"1","author":"Baruth","year":"2010","journal-title":"Trans Neurosci"},{"issue":"2","key":"10.1016\/j.jaac.2022.05.012_bib36","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1089\/cap.2015.0053","article-title":"The effectiveness and tolerability of central nervous system stimulants in school-age children with attention-deficit\/hyperactivity disorder and disruptive mood dysregulation disorder across home and school","volume":"26","author":"Baweja","year":"2016","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"4","key":"10.1016\/j.jaac.2022.05.012_bib37","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s10803-012-1624-7","article-title":"A\u00a0pilot study of parent training in young children with autism spectrum disorders and disruptive behavior","volume":"43","author":"Bearss","year":"2013","journal-title":"J\u00a0Autism Dev Disord"},{"issue":"15","key":"10.1016\/j.jaac.2022.05.012_bib38","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1001\/jama.2015.3150","article-title":"Effect of parent training vs parent education on behavioral problems in children with autism spectrum disorder","volume":"313","author":"Bearss","year":"2015","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.jaac.2022.05.012_bib39","first-page":"215","article-title":"Improvement in symptoms of autism spectrum disorder in children with the use of gastrin-releasing peptide: an open trial","volume":"39","author":"Becker","year":"2016","journal-title":"Clin\u00a0Neuropharmacol"},{"issue":"6","key":"10.1016\/j.jaac.2022.05.012_bib40","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/WNF.0000000000000368","article-title":"Risperidone combination therapy with propentofylline for treatment of irritability in autism spectrum disorders: a randomized, double-blind, placebo-controlled clinical trial","volume":"42","author":"Behmanesh","year":"2019","journal-title":"Clin Neuropharmacol"},{"issue":"11","key":"10.1016\/j.jaac.2022.05.012_bib41","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/FPC.0000000000000173","article-title":"Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder","volume":"25","author":"Bishop","year":"2015","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"10.1016\/j.jaac.2022.05.012_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13229-018-0241-5","article-title":"A\u00a0pilot dose finding study of pioglitazone in autistic children","volume":"9","author":"Capano","year":"2018","journal-title":"Mol Autism"},{"issue":"2","key":"10.1016\/j.jaac.2022.05.012_bib43","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/DBP.0b013e318165c100","article-title":"Risperidone use in children with Down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: a naturalistic study","volume":"29","author":"Capone","year":"2008","journal-title":"J\u00a0Dev Behav Pediatrics"},{"issue":"5","key":"10.1016\/j.jaac.2022.05.012_bib44","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1177\/1362361318810709","article-title":"Improving emotion regulation ability in autism: the Emotional Awareness and Skills Enhancement (EASE) program","volume":"23","author":"Conner","year":"2019","journal-title":"Autism"},{"issue":"3","key":"10.1016\/j.jaac.2022.05.012_bib45","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0004867416652735","article-title":"A\u00a0randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder","volume":"51","author":"Dean","year":"2017","journal-title":"Aust N Z J Psychiatry"},{"issue":"1","key":"10.1016\/j.jaac.2022.05.012_bib46","article-title":"Treatment of children with attention-deficit\/hyperactivity disorder (ADHD) and irritability: results from the Multimodal Treatment Study of Children With ADHD (MTA)","volume":"54","author":"de la Cruz","year":"2015","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"10.1016\/j.jaac.2022.05.012_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198726","article-title":"Therapeutic body wraps (TBW) for treatment of severe injurious behaviour in children with autism spectrum disorder (ASD): a 3-month randomized controlled feasibility study","volume":"13","author":"Delion","year":"2018","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jaac.2022.05.012_bib48","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/phar.2271","article-title":"Pharmacotherapy of autism spectrum disorder: results from the randomized BAART clinical trial","volume":"39","author":"DeVane","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jaac.2022.05.012_bib49","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jpsychires.2014.07.011","article-title":"Impact of acamprosate on plasma amyloid-\u03b2 precursor protein in youth: a pilot analysis in Fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker","volume":"59","author":"Erickson","year":"2014","journal-title":"J\u00a0Psychiatr Res"},{"issue":"5","key":"10.1016\/j.jaac.2022.05.012_bib50","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1159\/000141508","article-title":"Olanzapine in the treatment of behavioral problems associated with autism: an open-label trial in Kuwait","volume":"17","author":"Fido","year":"2008","journal-title":"Med Princip Pract"},{"issue":"9","key":"10.1016\/j.jaac.2022.05.012_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaac.2014.05.008","article-title":"Risperidone added to parent training and stimulant medication: effects on attention-deficit\/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression","volume":"53","author":"Gadow","year":"2014","journal-title":"J\u00a0Am Acad Child Adolesc Psychiat"},{"issue":"4","key":"10.1016\/j.jaac.2022.05.012_bib52","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1017\/S1461145712000880","article-title":"Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial","volume":"16","author":"Ghaleiha","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"issue":"6","key":"10.1016\/j.jaac.2022.05.012_bib53","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40272-013-0036-2","article-title":"Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial","volume":"15","author":"Ghaleiha","year":"2013","journal-title":"Pediatr Drugs"},{"issue":"7","key":"10.1016\/j.jaac.2022.05.012_bib54","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1177\/0269881113508830","article-title":"Galantamine efficacy and tolerability as an augmentative therapy in autistic children: a randomized, double-blind, placebo-controlled trial","volume":"28","author":"Ghaleiha","year":"2014","journal-title":"J\u00a0Psychopharmacol"},{"issue":"1-2","key":"10.1016\/j.jaac.2022.05.012_bib55","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.psychres.2015.07.043","article-title":"A\u00a0pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: effects on aberrant behavior in children with autism","volume":"229","author":"Ghaleiha","year":"2015","journal-title":"Psychiatry Res"},{"issue":"9","key":"10.1016\/j.jaac.2022.05.012_bib56","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1089\/cap.2015.0175","article-title":"Minocycline as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind placebo-controlled trial","volume":"26","author":"Ghaleiha","year":"2016","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"1","key":"10.1016\/j.jaac.2022.05.012_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-244X-13-196","article-title":"A\u00a0randomized double blind placebo controlled clinical trial of N-acetylcysteine added to risperidone for treating autistic disorders","volume":"13","author":"Ghanizadeh","year":"2013","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1016\/j.jaac.2022.05.012_bib58","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pediatrneurol.2014.09.017","article-title":"A\u00a0randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism","volume":"52","author":"Ghanizadeh","year":"2015","journal-title":"Pediatr Neurol"},{"issue":"1","key":"10.1016\/j.jaac.2022.05.012_bib59","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1089\/cap.2017.0026","article-title":"l-Carnosine as an adjunctive therapy to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial","volume":"28","author":"Hajizadeh-Zaker","year":"2018","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2022.05.012_bib60","doi-asserted-by":"crossref","unstructured":"Haller SP, Stoddard J, Botz-Zapp C, et\u00a0al. A randomized controlled trial of computerized interpretation bias training for disruptive mood dysregulation disorder: a fast-fail study. J Am Acad Child Adolesc Psychiatry. 2021 Jun 17. https:\/\/doi.org\/10.1016\/j.jaac.2021.05.022","DOI":"10.1016\/j.jaac.2021.05.022"},{"issue":"8","key":"10.1016\/j.jaac.2022.05.012_bib61","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1097\/01.chi.0000223312.48406.6e","article-title":"Open-label, prospective trial of olanzapine in adolescents with subaverage intelligence and disruptive behavioral disorders","volume":"45","author":"Handen","year":"2006","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"11","key":"10.1016\/j.jaac.2022.05.012_bib62","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jaac.2015.08.013","article-title":"Atomoxetine, parent training, and their combination in children with autism spectrum disorder and attention-deficit\/hyperactivity disorder","volume":"54","author":"Handen","year":"2015","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"11","key":"10.1016\/j.jaac.2022.05.012_bib63","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.biopsych.2012.01.014","article-title":"A\u00a0randomized controlled pilot trial of oral N-acetylcysteine in children with autism","volume":"71","author":"Hardan","year":"2012","journal-title":"Biol Psychiatry"},{"issue":"4","key":"10.1016\/j.jaac.2022.05.012_bib64","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1089\/cap.2005.15.682","article-title":"A\u00a0double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders","volume":"15","author":"Hellings","year":"2005","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"2","key":"10.1016\/j.jaac.2022.05.012_bib65","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1089\/cap.2014.0003","article-title":"Loxapine add-on for adolescents and adults with autism spectrum disorders and irritability","volume":"25","author":"Hellings","year":"2015","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"2","key":"10.1016\/j.jaac.2022.05.012_bib66","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/jcpt.13076","article-title":"Resveratrol as adjunctive therapy in treatment of irritability in children with autism: a double-blind and placebo-controlled randomized trial","volume":"45","author":"Hendouei","year":"2020","journal-title":"J\u00a0Clin Pharm Ther"},{"issue":"4","key":"10.1016\/j.jaac.2022.05.012_bib67","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/npp.2009.202","article-title":"Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders","volume":"35","author":"Hollander","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.jaac.2022.05.012_bib68","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s10578-016-0704-x","article-title":"Aripiprazole in the treatment of irritability in children and adolescents with autism spectrum disorder in Japan: a randomized, double-blind, placebo-controlled study","volume":"48","author":"Ichikawa","year":"2017","journal-title":"Child Psychiatry Hum Dev"},{"issue":"2","key":"10.1016\/j.jaac.2022.05.012_bib69","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/pcn.12607","article-title":"An open-label extension long-term study of the safety and efficacy of aripiprazole for irritability in children and adolescents with autistic disorder in Japan","volume":"72","author":"Ichikawa","year":"2018","journal-title":"Psychiatry Clinical Neurosci"},{"issue":"5","key":"10.1016\/j.jaac.2022.05.012_bib70","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/WNF.0b013e3182a31ec0","article-title":"Effectiveness and tolerability of switching to aripiprazole from risperidone in subjects with autism spectrum disorders: a prospective open-label study","volume":"36","author":"Ishitobi","year":"2013","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"10.1016\/j.jaac.2022.05.012_bib71","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/00004714-200210000-00003","article-title":"Open-label study of olanzapine in children with pervasive developmental disorder","volume":"22","author":"Kemner","year":"2002","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"10","key":"10.1016\/j.jaac.2022.05.012_bib72","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1089\/cap.2012.0058","article-title":"An open-label extension study of the safety and efficacy of risperidone in children and adolescents with autistic disorder","volume":"23","author":"Kent","year":"2013","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"8","key":"10.1016\/j.jaac.2022.05.012_bib73","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s10803-012-1723-5","article-title":"Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study","volume":"43","author":"Kent","year":"2013","journal-title":"J\u00a0Autism Dev Disord"},{"key":"10.1016\/j.jaac.2022.05.012_bib74","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijdevneu.2018.06.009","article-title":"Hesperetin and it nanocrystals ameliorate social behavior deficits and oxido-inflammatory stress in rat model of autism","volume":"69","author":"Khalaj","year":"2018","journal-title":"Int J Dev Neurosci"},{"issue":"6","key":"10.1016\/j.jaac.2022.05.012_bib75","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1089\/cap.2017.0152","article-title":"Aripiprazole for irritability in Asian children and adolescents with autistic disorder: a 12-week, multinational, multicenter, prospective open-label study","volume":"28","author":"Kim","year":"2018","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"5","key":"10.1016\/j.jaac.2022.05.012_bib76","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40501-018-0141-5","article-title":"Psychosocial treatment of irritability in youth","author":"Kircanski","year":"2018","journal-title":"Curr Treat Options Psychiatry"},{"issue":"5","key":"10.1016\/j.jaac.2022.05.012_bib77","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1089\/cap.2012.0127","article-title":"Tetrahydrobiopterin as a treatment for autism spectrum disorders: a double-blind, placebo-controlled trial","volume":"23","author":"Klaiman","year":"2013","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"3","key":"10.1016\/j.jaac.2022.05.012_bib78","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1089\/cap.2010.0123","article-title":"An open-label trial of risperidone in children and adolescents with severe mood dysregulation","volume":"21","author":"Krieger","year":"2011","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"5","key":"10.1016\/j.jaac.2022.05.012_bib79","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ejpn.2018.05.010","article-title":"Cognitive behavioral therapy for children with autism spectrum disorder: a prospective observational study","volume":"22","author":"Kurz","year":"2018","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.jaac.2022.05.012_bib80","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/5584_2018_234","article-title":"Effects of low-level laser therapy in autism spectrum disorder","author":"Leisman","year":"2018","journal-title":"Clin Med Res"},{"issue":"4","key":"10.1016\/j.jaac.2022.05.012_bib81","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s10803-015-2628-x","article-title":"Lurasidone for the treatment of irritability associated with autistic disorder","volume":"46","author":"Loebel","year":"2016","journal-title":"J\u00a0Autism Dev Disord"},{"issue":"12","key":"10.1016\/j.jaac.2022.05.012_bib82","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1007\/s00787-019-01333-5","article-title":"Baclofen as an adjuvant therapy for autism: a randomized, double-blind, placebo-controlled trial","volume":"28","author":"Mahdavinasab","year":"2019","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"2","key":"10.1016\/j.jaac.2022.05.012_bib83","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/WNF.0000000000000382","article-title":"Prednisolone as adjunctive treatment to risperidone in children with regressive type of autism spectrum disorder: a randomized, placebo-controlled trial","volume":"43","author":"Malek","year":"2020","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"10.1016\/j.jaac.2022.05.012_bib84","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1089\/cap.2006.0126","article-title":"Ziprasidone in adolescents with autism: an open-label pilot study","volume":"17","author":"Malone","year":"2007","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"6","key":"10.1016\/j.jaac.2022.05.012_bib85","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1089\/cap.2013.0143","article-title":"Aripiprazole decreases irritability in 12 out of 14 youth with autism spectrum disorders","volume":"24","author":"Maloney","year":"2014","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"11","key":"10.1016\/j.jaac.2022.05.012_bib86","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/CHI.0b013e3181b76658","article-title":"A\u00a0placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder","volume":"48","author":"Marcus","year":"2009","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"10.1016\/j.jaac.2022.05.012_bib87","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1089\/cap.2009.0121","article-title":"Aripiprazole in the treatment of irritability in pediatric patients (aged 6\u201317 years) with autistic disorder: results from a 52-week, open-label study","volume":"21","author":"Marcus","year":"2011","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2022.05.012_bib88","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jsbmb.2018.10.017","article-title":"A\u00a0randomised controlled trial of vitamin D and omega-3 long chain polyunsaturated fatty acids in the treatment of irritability and hyperactivity among children with autism spectrum disorder","volume":"187","author":"Mazahery","year":"2019","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"issue":"1","key":"10.1016\/j.jaac.2022.05.012_bib89","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/aur.2204","article-title":"Cognitive behavioral treatment of insomnia in school-aged children with autism spectrum disorder: a pilot feasibility study","volume":"13","author":"McCrae","year":"2020","journal-title":"Autism Res"},{"issue":"2","key":"10.1016\/j.jaac.2022.05.012_bib90","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1089\/cap.2009.0011","article-title":"Micronutrients versus standard medication management in autism: a naturalistic case\u2013control study","volume":"20","author":"Mehl-Madrona","year":"2010","journal-title":"J\u00a0Child Adolesc Psychopharmacology"},{"issue":"6","key":"10.1016\/j.jaac.2022.05.012_bib91","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/da.22761","article-title":"Interpersonal psychotherapy for mood and behavior dysregulation: pilot randomized trial","volume":"35","author":"Miller","year":"2018","journal-title":"Depress Anxiety"},{"issue":"1","key":"10.1016\/j.jaac.2022.05.012_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-244X-12-215","article-title":"Yokukansan (TJ-54) for treatment of pervasive developmental disorder not otherwise specified and Asperger\u2019s disorder: a 12-week prospective, open-label study","volume":"12","author":"Miyaoka","year":"2012","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1016\/j.jaac.2022.05.012_bib93","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1089\/cap.2017.0055","article-title":"Simvastatin as an adjunctive therapy to risperidone in treatment of autism: a randomized, double-blind, placebo-controlled clinical trial","volume":"28","author":"Moazen-Zadeh","year":"2018","journal-title":"J\u00a0Child Adolesc Psychopharmacology"},{"issue":"6","key":"10.1016\/j.jaac.2022.05.012_bib94","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/WNF.0b013e3182a9339d","article-title":"Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study","volume":"36","author":"Mohammadi","year":"2013","journal-title":"Clin Neuropharmacol"},{"issue":"7","key":"10.1016\/j.jaac.2022.05.012_bib95","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/pcn.13016","article-title":"Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: a randomized, double-blind, placebo-controlled clinical trial","volume":"74","author":"Momtazmanesh","year":"2020","journal-title":"Psychiatry Clin Neurosci"},{"issue":"6","key":"10.1016\/j.jaac.2022.05.012_bib96","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1089\/cap.2014.0158","article-title":"Pharmacogenetic study of serotonin transporter and 5HT2A genotypes in autism","volume":"25","author":"Najjar","year":"2015","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"5","key":"10.1016\/j.jaac.2022.05.012_bib97","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1089\/cap.2006.16.621","article-title":"A\u00a0prospective, open-label trial of galantamine in autistic disorder","volume":"16","author":"Nicolson","year":"2006","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"1","key":"10.1016\/j.jaac.2022.05.012_bib98","first-page":"87","article-title":"Venlafaxine has modest effects in autistic children","volume":"1","author":"Niederhofer","year":"2004","journal-title":"Clin Pract"},{"issue":"01","key":"10.1016\/j.jaac.2022.05.012_bib99","first-page":"19","article-title":"Comparing efficacy and side effects of memantine vs risperidone in the treatment of autistic disorder","volume":"50","author":"Nikvarz","year":"2017","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"10.1016\/j.jaac.2022.05.012_bib100","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/01.chi.0000153229.80215.a0","article-title":"An open-label trial of escitalopram in pervasive developmental disorders","volume":"44","author":"Owley","year":"2005","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"10","key":"10.1016\/j.jaac.2022.05.012_bib101","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1089\/cap.2018.0068","article-title":"Aripiprazole\/methylphenidate combination in children and adolescents with disruptive mood dysregulation disorder and attention-deficit\/hyperactivity disorder: an open-label study","volume":"28","author":"Pan","year":"2018","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"2","key":"10.1016\/j.jaac.2022.05.012_bib102","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10803-006-0234-7","article-title":"Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Pandina","year":"2007","journal-title":"J\u00a0Autism Dev Disord"},{"issue":"11","key":"10.1016\/j.jaac.2022.05.012_bib103","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1007\/s10803-017-3366-z","article-title":"Behavioral outcomes of specialized psychiatric hospitalization in the Autism Inpatient Collection (AIC): a multisite comparison","volume":"48","author":"Pedersen","year":"2018","journal-title":"J\u00a0Autism Dev Disord"},{"issue":"5","key":"10.1016\/j.jaac.2022.05.012_bib104","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1089\/cap.2006.16.599","article-title":"Open-label atomoxetine for attention-deficit\/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders","volume":"16","author":"Posey","year":"2006","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"11","key":"10.1016\/j.jaac.2022.05.012_bib105","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/archpsyc.62.11.1266","article-title":"Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity","volume":"62","year":"2005","journal-title":"Arch Gen Psychiatry"},{"issue":"7","key":"10.1016\/j.jaac.2022.05.012_bib106","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.pnpbp.2010.07.005","article-title":"Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder","volume":"34","author":"Rezaei","year":"2010","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"7","key":"10.1016\/j.jaac.2022.05.012_bib107","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/aur.2308","article-title":"Addressing challenging behavior during hospitalizations for children with autism: a pilot applied behavior analysis randomized controlled trial","volume":"13","author":"Sanders","year":"2020","journal-title":"Autism Res"},{"issue":"12","key":"10.1016\/j.jaac.2022.05.012_bib108","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1176\/appi.ajp.2015.15010055","article-title":"Extended-release guanfacine for hyperactivity in children with autism spectrum disorder","volume":"172","author":"Scahill","year":"2015","journal-title":"Am J Psychiatry"},{"issue":"5","key":"10.1016\/j.jaac.2022.05.012_bib109","doi-asserted-by":"crossref","first-page":"e634","DOI":"10.1542\/peds.2003-0264-F","article-title":"Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders","volume":"114","author":"Shea","year":"2004","journal-title":"Pediatrics"},{"issue":"10","key":"10.1016\/j.jaac.2022.05.012_bib110","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.jaac.2016.06.015","article-title":"Atomoxetine and parent training for children with autism and attention-deficit\/hyperactivity disorder: a 24-week extension study","volume":"55","author":"Smith","year":"2016","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"7","key":"10.1016\/j.jaac.2022.05.012_bib111","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jaac.2020.07.888","article-title":"Bumetanide for Core Symptoms of Autism Spectrum Disorder (BAMBI): a single center, double-blinded, participant-randomized, placebo-controlled, phase-2 superiority trial","volume":"60","author":"Sprengers","year":"2021","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"10.1016\/j.jaac.2022.05.012_bib112","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/cap.2008.093","article-title":"Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger\u2019s disorder: a 14-week, prospective, open-label study","volume":"19","author":"Stigler","year":"2009","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"2","key":"10.1016\/j.jaac.2022.05.012_bib113","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00213-012-2711-3","article-title":"Paliperidone for irritability in adolescents and young adults with autistic disorder","volume":"223","author":"Stigler","year":"2012","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1016\/j.jaac.2022.05.012_bib114","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.clinthera.2013.04.006","article-title":"An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders","volume":"35","author":"Taliou","year":"2013","journal-title":"Clin Ther"},{"issue":"10","key":"10.1016\/j.jaac.2022.05.012_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaac.2020.08.023","article-title":"A\u00a0double-blind randomized placebo-controlled trial of citalopram adjunctive to stimulant medication in youth with chronic severe irritability","volume":"59","author":"Towbin","year":"2020","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"7","key":"10.1016\/j.jaac.2022.05.012_bib116","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/npp.2016.237","article-title":"Arbaclofen in children and adolescents with autism spectrum disorder: a randomized, controlled, phase 2 trial","volume":"42","author":"Veenstra-VanderWeele","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.jaac.2022.05.012_bib117","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1089\/cap.2012.0108","article-title":"Yokukansan (TJ-54) for irritability associated with pervasive developmental disorder in children and adolescents: a 12-week prospective, open-label study","volume":"23","author":"Wake","year":"2013","journal-title":"Journal of child and adolescent psychopharmacology"},{"issue":"6","key":"10.1016\/j.jaac.2022.05.012_bib118","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1089\/cap.2008.065","article-title":"The efficacy and tolerability of methylphenidate and behavior modification in children with attention-deficit\/hyperactivity disorder and severe mood dysregulation","volume":"18","author":"Waxmonsky","year":"2008","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"11","key":"10.1016\/j.jaac.2022.05.012_bib119","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.4088\/JCP.09m05496pur","article-title":"Effects of atomoxetine with and without behavior therapy on the school and home functioning of children with attention-deficit\/hyperactivity disorder","volume":"71","author":"Waxmonsky","year":"2010","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.jaac.2022.05.012_bib120","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jaac.2015.12.011","article-title":"A\u00a0randomized clinical trial of an integrative group therapy for children with severe mood dysregulation","volume":"55","author":"Waxmonsky","year":"2016","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"10.1016\/j.jaac.2022.05.012_bib121","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0165-1781(95)02749-M","article-title":"Placebo-controlled acute dosage naltrexone study in young autistic children","volume":"58","author":"Willemsen-Swinkels","year":"1995","journal-title":"Psychiatry Res"},{"issue":"12","key":"10.1016\/j.jaac.2022.05.012_bib122","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/0006-3223(95)00297-9","article-title":"The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study","volume":"39","author":"Willemsen-Swinkels","year":"1996","journal-title":"Biol Psychiatry"},{"issue":"9","key":"10.1016\/j.jaac.2022.05.012_bib123","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1007\/s10803-018-3562-5","article-title":"A\u00a0randomized placebo-controlled cross-over pilot study of riluzole for drug-refractory irritability in autism spectrum disorder","volume":"48","author":"Wink","year":"2018","journal-title":"J\u00a0Autism Dev Disord"},{"issue":"5","key":"10.1016\/j.jaac.2022.05.012_bib124","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1089\/cap.2017.0124","article-title":"Improvements in irritability with open-label methylphenidate treatment in youth with comorbid attention deficit\/hyperactivity disorder and disruptive mood dysregulation disorder","volume":"28","author":"Winters","year":"2018","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"3","key":"10.1016\/j.jaac.2022.05.012_bib125","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/jcpt.12518","article-title":"Impact of providing psychiatry specialty pharmacist intervention on reducing drug-related problems among children with autism spectrum disorder related to disruptive behavioural symptoms: a prospective randomized open-label study","volume":"42","author":"Wongpakaran","year":"2017","journal-title":"J\u00a0Clin Pharm Ther"},{"issue":"2","key":"10.1016\/j.jaac.2022.05.012_bib126","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1001\/jamapsychiatry.2018.3421","article-title":"Association of antipsychotic treatment with risk of unexpected death among children and youths","volume":"76","author":"Ray","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.jaac.2022.05.012_bib127","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jaac.2016.03.014","article-title":"Severely aggressive children receiving stimulant medication versus stimulant and risperidone: 12-month follow-up of the TOSCA trial","volume":"55","author":"Gadow","year":"2016","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"10.1016\/j.jaac.2022.05.012_bib128","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s13142-014-0265-0","article-title":"Introduction to SMART designs for the development of adaptive interventions: with application to weight loss research","volume":"4","author":"Almirall","year":"2014","journal-title":"Trans Behav Med"},{"issue":"4","key":"10.1016\/j.jaac.2022.05.012_bib129","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1080\/15374416.2015.1055859","article-title":"Comparative cost analysis of sequential, adaptive, behavioral, pharmacological, and combined treatments for childhood ADHD","volume":"45","author":"Page","year":"2016","journal-title":"J\u00a0Clin Child Adolesc Psychol"},{"issue":"4","key":"10.1016\/j.jaac.2022.05.012_bib130","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1080\/15374416.2015.1105138","article-title":"Treatment sequencing for childhood ADHD: a multiple-randomization study of adaptive medication and behavioral interventions","volume":"45","author":"Pelham","year":"2016","journal-title":"J\u00a0Clin Child Adolesc Psychol"},{"issue":"2","key":"10.1016\/j.jaac.2022.05.012_bib131","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jaac.2019.12.009","article-title":"Stepped treatment for attention-deficit\/hyperactivity disorder and aggressive behavior: a randomized, controlled trial of adjunctive risperidone, divalproex sodium, or placebo after stimulant medication optimization","volume":"60","author":"Blader","year":"2021","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"12","key":"10.1016\/j.jaac.2022.05.012_bib132","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.jaac.2020.09.008","article-title":"A\u00a0transdiagnostic symptom requires a transdiagnostic approach: neural mechanisms of pediatric irritability","volume":"59","author":"Tseng","year":"2009","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"10.1016\/j.jaac.2022.05.012_bib133","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.chc.2021.04.011","article-title":"A\u00a0modular, transdiagnostic approach to treating severe irritability in children and adolescents","volume":"30","author":"Evans","year":"2021","journal-title":"Child Adolesc Psychiatr Clin"},{"issue":"6","key":"10.1016\/j.jaac.2022.05.012_bib134","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s10802-013-9843-8","article-title":"A\u00a0dose-ranging study of behavioral and pharmacological treatment in social settings for children with ADHD","volume":"42","author":"Pelham","year":"2014","journal-title":"J\u00a0Abnorm Child Psychol"}],"container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856722003033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856722003033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:33:53Z","timestamp":1760193233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890856722003033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":134,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0890856722003033"],"URL":"https:\/\/doi.org\/10.1016\/j.jaac.2022.05.012","relation":{},"ISSN":["0890-8567"],"issn-type":[{"value":"0890-8567","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic Review and Meta-analysis: Pharmacological and Nonpharmacological Interventions for Persistent Nonepisodic Irritability","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Child & Adolescent Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaac.2022.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a92022 American Academy of Child and Adolescent Psychiatry","name":"copyright","label":"Copyright"}]}}